The DOI matches its Crossref record; 81 of the 81 references it cites were found in a registry or an index.
Boron in drug design: Recent advances in the development of new therapeutic agents
Open accessAbstract
Advances in the field of boron chemistry have expanded the application of this element in Medicinal Chemistry. Boron-containing compounds represent a new class for medicinal chemists to use in their drug designs. Bortezomib (Velcade®), a dipeptide boronic acid approved by the FDA in 2003 for treatment of multiple myeloma, paved the way for the discovery of new boron-containing compounds. After its approval, two other boron-containing compounds have been approved, tavaborole (Kerydin®) for the treatment of onychomicosis and crisaborole (Eucrisa®) for the treatment of mild to moderate atopic dermatitis. A number of boron-containing compounds have been described and evaluated for a plethora of therapeutic applications. The present review is intended to highlight the recent advances related to boron-containing compounds and their therapeutic applications. Here, we focused only in those most biologically active compounds with proven in vitro and/or in vivo efficacy in the therapeutic area published in the last years.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Alterio, V., Di Fiore, A., D’Ambrosio, K., Supuran, C. T., & De Simone, G. (2012) · Chemical Reviews · doi:10.1021/cr200176r · Cited by 1,238
The Sterile Inflammatory Response
Rock, K. L., Latz, E., Ontiveros, F., & Kono, H. (2010) · Annual Review of Immunology · doi:10.1146/annurev-immunol-030409-101311 · Cited by 865
The proteasome: overview of structure and functions
TANAKA, K. (2009) · Proceedings of the Japan Academy, Series B · doi:10.2183/pjab.85.12 · Cited by 862
Aminoacyl-tRNA Synthetases, the Genetic Code, and the Evolutionary Process
Woese, C. R., Olsen, G. J., Ibba, M., & Söll, D. (2000) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.64.1.202-236.2000 · Cited by 706
The role of CXC chemokines and their receptors in cancer
Vandercappellen, J., Van Damme, J., & Struyf, S. (2008) · Cancer Letters · doi:10.1016/j.canlet.2008.04.050 · Cited by 643
The proteasome: structure, function, and role in the cell
ADAMS, J. (2003) · Cancer Treatment Reviews · doi:10.1016/s0305-7372(03)00081-1 · Cited by 585
Boronic acid compounds as potential pharmaceutical agents
Yang, W., Gao, X., & Wang, B. (2003) · Medicinal Research Reviews · doi:10.1002/med.10043 · Cited by 502
Therapeutic Potential of Boron-Containing Compounds
Baker, S. J., Ding, C. Z., Akama, T., Zhang, Y.-K., Hernandez, V., & Xia, Y. (2009) · Future Medicinal Chemistry · doi:10.4155/fmc.09.71 · Cited by 373
Challenges and Opportunities for the Application of Boron Clusters in Drug Design
Leśnikowski, Z. J. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01932 · Cited by 348
The pharmacological landscape and therapeutic potential of serine hydrolases
Bachovchin, D. A., & Cravatt, B. F. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3620 · Cited by 308
SCYX-7158, an Orally-Active Benzoxaborole for the Treatment of Stage 2 Human African Trypanosomiasis
Jacobs, R. T., Nare, B., Wring, S. A., Orr, M. D., Chen, D., Sligar, J. M., Jenks, M. X., Noe, R. A., Bowling, T. S., Mercer, L. T., et al. (2011) · PLoS Neglected Tropical Diseases · doi:10.1371/journal.pntd.0001151 · Cited by 305
Groll, M., Heinemeyer, W., Jäger, S., Ullrich, T., Bochtler, M., Wolf, D. H., & Huber, R. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.20.10976 · Cited by 300
Richardson, P. G., Hideshima, T., & Anderson, K. C. (2003) · Cancer Control · doi:10.1177/107327480301000502 · Cited by 292
Recent Developments in the Chemistry and Biological Applications of Benzoxaboroles
Adamczyk-Woźniak, A., Borys, K. M., & Sporzyński, A. (2015) · Chemical Reviews · doi:10.1021/cr500642d · Cited by 239
Bacterial, fungal and protozoan carbonic anhydrases as drug targets
Capasso, C., & Supuran, C. T. (2015) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2015.1067685 · Cited by 219
Akama, T., Baker, S. J., Zhang, Y.-K., Hernandez, V., Zhou, H., Sanders, V., Freund, Y., Kimura, R., Maples, K. R., & Plattner, J. J. (2009) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2009.03.007 · Cited by 218
Role of Proteasomes in Cellular Regulation
(2008) · International Review of Cell and Molecular Biology · doi:10.1016/s1937-6448(08)00602-3 · Cited by 175
Ban, H. S., & Nakamura, H. (2015) · The Chemical Record · doi:10.1002/tcr.201402100 · Cited by 167
Li, X., Hernandez, V., Rock, F. L., Choi, W., Mak, Y. S. L., Mohan, M., Mao, W., Zhou, Y., Easom, E. E., Plattner, J. J., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00631 · Cited by 167
Current Challenges in Antimicrobial Chemotherapy: Focus on β-Lactamase Inhibition
Bebrone, C., Lassaux, P., Vercheval, L., Sohier, J.-S., Jehaes, A., Sauvage, E., & Galleni, M. (2010) · Drugs · doi:10.2165/11318430-000000000-00000 · Cited by 159
Peptide–Boronic Acid Inhibitors of Flaviviral Proteases: Medicinal Chemistry and Structural Biology
Nitsche, C., Zhang, L., Weigel, L. F., Schilz, J., Graf, D., Bartenschlager, R. F. W., Hilgenfeld, R., & Klein, C. D. P. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01021 · Cited by 154
Sonoiki, E., Ng, C. L., Lee, M., Guo, D., Zhang, Y.-K., Zhou, Y., Alley, M. R. K., Ahyong, V., Sanz, L. M., Lafuente-Monasterio, M. J., et al. (2017) · Nature Communications · doi:10.1038/ncomms14574 · Cited by 145
Synthesis of biologically active boron-containing compounds
Yang, F., Zhu, M., Zhang, J., & Zhou, H. (2017) · MedChemComm · doi:10.1039/c7md00552k · Cited by 133
Benzoxaborole compounds for therapeutic uses: a patent review (2010- 2018)
Nocentini, A., Supuran, C. T., & Winum, J. (2018) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2018.1473379 · Cited by 127
Recent developments with boron as a platform for novel drug design
Lesnikowski, Z. J. (2016) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2016.1174687 · Cited by 121
Palencia, A., Li, X., Bu, W., Choi, W., Ding, C. Z., Easom, E. E., Feng, L., Hernandez, V. S., Houston, P., Liu, L., et al. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01339-16 · Cited by 121
Boron‐based phosphodiesterase inhibitors show novel binding of boron to PDE4 bimetal center
Freund, Y. R., Akama, T., Alley, M. R. K., et al. (2012) · FEBS Letters · doi:10.1016/j.febslet.2012.07.058 · Cited by 113
β -lactamase inhibitors. The inhibition of serine β -lactamases by specific boronic acids
Crompton, I. E., Cuthbert, B. K., Lowe, G. M., & Waley, S. G. (1988) · Biochemical Journal · doi:10.1042/bj2510453 · Cited by 105
Benzoxaborole as a new chemotype for carbonic anhydrase inhibition
Alterio, V., Cadoni, R., Esposito, D., Vullo, D., Fiore, A. D., Monti, S. M., Caporale, A., Ruvo, M., Sechi, M., Dumy, P., et al. (2016) · Chemical Communications · doi:10.1039/c6cc06399c · Cited by 95
Boron-Based Inhibitors of the NLRP3 Inflammasome
Baldwin, A. G., Rivers‐Auty, J., Daniels, M. J. D., White, C., Schwalbe, C. H., Schilling, T., Hammadi, H., Jaiyong, P., Spencer, N. G., England, H., et al. (2017) · Cell chemical biology · doi:10.1016/j.chembiol.2017.08.011 · Cited by 95
Kosmidis, C., Schindler, B. D., Jacinto, P. L., Patel, D., Bains, K., Seo, S. M., & Kaatz, G. W. (2012) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2012.04.014 · Cited by 94
Dong, C., Virtucio, C., Zemska, O., Baltazar, G., Zhou, Y., Baía, D., Jones-Iatauro, S., Sexton, H., Martin, S., Dee, J., et al. (2016) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.116.232819 · Cited by 94
Liu, J., Zheng, S., Akerstrom, V. L., Yuan, C., Ma, Y., Zhong, Q., Zhang, C., Zhang, Q., Guo, S., Ma, P., et al. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00753 · Cited by 86
Antimalarial Benzoxaboroles Target Plasmodium falciparum Leucyl-tRNA Synthetase
Sonoiki, E., Palencia, A., Guo, D., Ahyong, V., Dong, C., Li, X., Hernandez, V. S., Zhang, Y., Choi, W., Gut, J., et al. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00820-16 · Cited by 76
Boron Therapeutics on the Horizon
Groziak, M. P. (2001) · American Journal of Therapeutics · doi:10.1097/00045391-200109000-00005 · Cited by 69
10-Boronic acid substituted camptothecin as prodrug of SN-38
Wang, L., Xie, S. P., Ma, L., Chen, Y., & Lu, W. P. (2016) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2016.03.063 · Cited by 67
Zhang, Y.-K., Plattner, J. J., Easom, E. E., Jacobs, R. T., Guo, D., Freund, Y. R., Berry, P. W., Ciaravino, V., Erve, J. C. L., Rosenthal, P. J., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00621 · Cited by 66
Chong, P. Y., Shotwell, J. B., Miller, J. F., Price, D. J., Maynard, A., Voitenleitner, C., Mathis, A., Williams, S. P., Pouliot, J. J., Creech, K. L., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01719 · Cited by 60
Diazaborines as New Inhibitors of Human Neutrophil Elastase
António, J. P. M., Gonçalves, L., Guedes, R. C., et al. (2018) · ACS Omega · doi:10.1021/acsomega.8b00702 · Cited by 57
Rojas, L. J., Taracila, M. A., Papp‐Wallace, K. M., Bethel, C. R., Caselli, E., Romagnoli, C., Winkler, M., Spellberg, B. J., Prati, F., & Bonomo, R. A. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02641-15 · Cited by 56
Click Chemistry in Lead Optimization of Boronic Acids as β-Lactamase Inhibitors
Caselli, E., Romagnoli, C., Vahabi, R., Taracila, M. A., Bonomo, R. A., & Prati, F. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00341 · Cited by 52
Targeting Class A and C Serine β-Lactamases with a Broad-Spectrum Boronic Acid Derivative
Tondi, D., Venturelli, A., Bonnet, R., Pozzi, C., Shoichet, B. K., & Costi, M. P. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm5006572 · Cited by 52
Akama, T., Zhang, Y.-K., Freund, Y. R., Berry, P. W., Lee, J., Easom, E. E., Jacobs, R. T., Plattner, J. J., Witty, M. J., Peter, R., et al. (2017) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2017.11.028 · Cited by 45
Jacobs, R. T., Lunde, C. S., Freund, Y. R., Hernandez, V. S., Li, X., Xia, Y., Carter, D. S., Berry, P. W., Halladay, J. S., Rock, F. L., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01854 · Cited by 43
Santucci, M., Spyrakis, F., Cross, S., Quotadamo, A., Farina, D. S. F., Tondi, D., Luca, F. D., Docquier, J., Prieto, A. I., Ibacache‐Quiroga, C., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-17399-7 · Cited by 42
Bocxlaer, K. V., Gaukel, E., Hauser, D., Park, S. H., Schock, S., Yardley, V., Randolph, R., Plattner, J. J., Merchant, T., Croft, S. L., et al. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02419-17 · Cited by 42
McKinney, D. C., Zhou, F., Eyermann, C. J., Ferguson, A. D., Prince, D. B., Breen, J. N., GIACOBBE, R. A., Lahiri, S. D., & Verheijen, J. C. (2015) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.5b00031 · Cited by 40
Lu, C., Hu, J., Wang, Z., Xie, S., Pan, T., Huang, L., & Li, X. (2018) · MedChemComm · doi:10.1039/c8md00315g · Cited by 40
Bouza, A. A., Swanson, H. C., Smolen, K. A., VanDine, A. L., Taracila, M. A., Romagnoli, C., Caselli, E., Prati, F., Bonomo, R. A., Powers, R. A., et al. (2017) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.7b00152 · Cited by 39
Zhang, Y.-K., Plattner, J. J., Easom, E. E., Jacobs, R. T., Guo, D., Sanders, V., Freund, Y. R., Campo, B., Rosenthal, P. J., Bu, W., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00678 · Cited by 38
Maeda, D. Y., Peck, A. M., Schuler, A. D., Quinn, M. T., Kirpotina, L. N., Wicomb, W. N., Fan, G.-H., & Zebala, J. A. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm500827t · Cited by 37
Stilbene Boronic Acids Form a Covalent Bond with Human Transthyretin and Inhibit Its Aggregation
Smith, T. P., Windsor, I. W., Forest, K. T., & Raines, R. T. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00952 · Cited by 35
Urea-containing peptide boronic acids as potent proteasome inhibitors
Han, L., Yuan, X., Wu, X., Li, R., Xu, B., Cheng, Q., Zm, L., Zhou, T.-Y., An, H.-Y., Wang, X., et al. (2016) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2016.10.023 · Cited by 34
Wang, W., Yin, R., Zhang, M., Yu, R., Hao, C., Zhang, L., & Jiang, T. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00326 · Cited by 34
Zhang, Y.-K., Plattner, J. J., Easom, E. E., Zhou, Y., Akama, T., Bu, W., White, W. H., Defauw, J. M., Winkle, J. R., Balko, T. W., et al. (2015) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2015.10.044 · Cited by 33
The 7-phenyl benzoxaborole series is active against Mycobacterium tuberculosis
Korkegian, A., O’Malley, T., Xia, Y., Zhou, Y., Carter, D. S., Sunde, B., Flint, L., Thompson, D., Ioerger, T. R., Sacchettini, J. C., et al. (2017) · Tuberculosis · doi:10.1016/j.tube.2017.11.003 · Cited by 31
Design, Synthesis and Evaluation of Oxazaborine Inhibitors of the NLRP3 Inflammasome
Baldwin, A. G., Tapia, V. S., Swanton, T., White, C., Beswick, J. A., Brough, D., & Freeman, S. (2018) · ChemMedChem · doi:10.1002/cmdc.201700731 · Cited by 31
Lei, M., Feng, H., Bai, E., Zhou, H., Wang, J., Qin, Y., Zhang, H., Wang, X., Liu, Z., Hai, O., et al. (2018) · Organic & Biomolecular Chemistry · doi:10.1039/c8ob02668h · Cited by 31
Estrogen receptor downregulators: New antihormonal therapy for advanced breast cancer
Robertson, J. F. R. (2002) · Clinical Therapeutics · doi:10.1016/s0149-2918(02)85032-9 · Cited by 28
Boronic acid inhibitors of the class A β-lactamase KPC-2
Zhou, J., Stapleton, P. D., Haider, S. M., & Healy, J. (2018) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2018.04.055 · Cited by 28
Psurski, M., Łupicka‐Słowik, A., Adamczyk‐Woźniak, A., Wietrzyk, J., & Sporzyński, A. (2018) · Investigational New Drugs · doi:10.1007/s10637-018-0611-z · Cited by 28
Kawamura, S., Unno, Y., Asai, A., Arisawa, M., & Shuto, S. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm500045x · Cited by 26
Zhang, Y.-K., Plattner, J. J., Easom, E. E., Akama, T., Zhou, Y., White, W. H., Defauw, J. M., Winkle, J. R., Balko, T. W., Cao, J., et al. (2016) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2016.04.093 · Cited by 24
Novel pyrrolobenzoxaboroles: Design, synthesis, and biological evaluation against Trypanosoma brucei
Wu, P., Zhang, J., Meng, Q., Nare, B., Jacobs, R. T., & Zhou, H. (2014) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2014.04.079 · Cited by 23
Scarbaci, K., Troiano, V., Ettari, R., Pinto, A., Micale, N., Giovanni, C. D., Cerchia, C., Schirmeister, T., Novellino, E., Lavecchia, A., et al. (2014) · ChemMedChem · doi:10.1002/cmdc.201402075 · Cited by 20
Cinnamoyl-Oxaborole Amides: Synthesis and Their in Vitro Biological Activity
Gumbo, M., Beteck, R. M., Mandizvo, T., Seldon, R., Warner, D. F., Hoppe, H. C., Isaacs, M. L., Laming, D., Tam, C. C., Cheng, L. W., et al. (2018) · Molecules · doi:10.3390/molecules23082038 · Cited by 20
Szałaj, N., Lu, L., Benediktsdottir, A., Zamaratski, E., Cao, S., Olanders, G., Hedgecock, C. J. R., Karlén, A., Erdélyi, M., Hughes, D., et al. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.08.086 · Cited by 19
Synthesis and biological activity of peptide proline-boronic acids as proteasome inhibitors
Han, L., Wen, Y., Li, R., Xu, B., Ge, Z., Wang, X., Cheng, T., Cui, J., & Li, R. (2017) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2017.05.049 · Cited by 18
Zhang, W., Bai, H., Han, L., Zhang, H., Xu, B., Cui, J., Wang, X., Ge, Z., & Li, R. (2018) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2018.06.004 · Cited by 18
Maeda, D. Y., Peck, A. M., Schuler, A. D., Quinn, M. T., Kirpotina, L. N., Wicomb, W. N., Auten, R. L., Gundla, R., & Zebala, J. A. (2015) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2015.04.041 · Cited by 16
Lei, M., Feng, H., Wang, C., Li, H., Shi, J., Wang, J., Liu, Z., Chen, S., Hu, S., & Zhu, Y. (2016) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2016.04.025 · Cited by 16
Ogiyama, T., Yamaguchi, M., Kurikawa, N., Honzumi, S., Yamamoto, Y., Sugiyama, D., & Inoue, S. (2016) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2016.06.022 · Cited by 16
Schuler, A. D., Engles, C. A., Maeda, D. Y., Quinn, M. T., Kirpotina, L. N., Wicomb, W. N., Mason, S. N., Auten, R. L., & Zebala, J. A. (2015) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2015.07.090 · Cited by 15
Arylboronic acids as dual-action FAAH and TRPV1 ligands
Morera, E., Marzo, V. D., Monti, L., Allarà, M., Moriello, A. S., Nalli, M., Ortar, G., & PETROCELLIS, L. D. (2016) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2016.01.071 · Cited by 15
Ge, Y., Li, A., Wu, J., Feng, H., Wang, L., Liu, H., Xu, Y., Xu, Q., Zhao, L., & Li, Y. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.01.034 · Cited by 15
Shi, J., Lei, M., Wu, W., Feng, H., Wang, J., Chen, S., Zhu, Y., Hu, S., Liu, Z., & Jiang, C. (2016) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2016.03.007 · Cited by 14
Synthesis and Evaluation of the Anticancer and Trypanocidal Activities of Boronic Tyrphostins
Hiller, N. D. J., Silva, N. A. D. A. E., Faria, R. X., Souza, A. L. A., Resende, J. A. L. C., Farias, A. B., Romeiro, N. C., & Martins, D. D. L. (2018) · ChemMedChem · doi:10.1002/cmdc.201800206 · Cited by 14
Lei, M., Feng, H., Bai, E., Zhou, H., Wang, J., Shi, J., Wang, X., Hu, S., Liu, Z., & Zhu, Y. (2018) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2018.06.020 · Cited by 12
A hit deconstruction approach for the discovery of fetal hemoglobin inducers
Benowitz, A. B., Eberl, H. C., Erickson‐Miller, C. L., Gilmartin, A. G., Gore, E. R., Montoute, M. N., & Wu, Z. (2018) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2018.10.032 · Cited by 12
Jin, H., Xu, Z., Li, D., & Huang, J. Y. (2014) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2013.12.011 · Cited by 7
Novel aromatic sulfonyl naphthalene-based boronates as 20S proteasome inhibitors.
Liu, H., Wu, J.-W., Ge, Y.-Y., Li, A., Li, J., Liu, Z.-S., Xu, Y.-G., Xu, Q.-X., & Li, Y. (2018) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2018.01.017 · Cited by 7
Cited by
U.S. FDA Approved Drugs from 2015–June 2020: A Perspective
Bhutani, P., Joshi, G., Raja, N., Bachhav, N., Rajanna, P. K., Bhutani, H., Paul, A. T., & Kumar, R. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01786 · Cited by 815
Amide Bond Bioisosteres: Strategies, Synthesis, and Successes
Kumari, S., Carmona, A. V., Tiwari, A. K., & Trippier, P. C. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00530 · Cited by 654
Grams, R. J., Santos, W. L., Scorei, I. R., Abad-García, A., Rosenblum, C. A., Bita, A., Cerecetto, H., Viñas, C., & Soriano-Ursúa, M. A. (2024) · Chemical Reviews · doi:10.1021/acs.chemrev.3c00663 · Cited by 377
Wang, P., Gong, Q., Hu, J., Li, X., & Zhang, X. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01704 · Cited by 270
Metadata
- Authors
- Fernandes, G. F. S., Denny, W. A., & Dos Santos, J. L.
- Venue
- European Journal of Medicinal Chemistry
- Publisher
- Elsevier BV
- Published
- 2019-10
- Volume
- 179
- Pages
- 791-804
- ISSN
- 0223-5234 (ISSN-L)
- OpenAlex
- W2955791106
- Cited by
- 269
- References
- 81
- FWCI
- 10.55
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.